Related Experiment Videos
Statin trials and goals of cholesterol-lowering therapy after AMI
1University of Oslo, Cardiology Department, Aker Hospital, N 0514, Oslo, Norway.
Insights
Statins significantly reduce coronary heart disease (CHD) mortality and events. However, optimal low-density-lipoprotein (LDL) cholesterol targets for aggressive treatment remain debated, requiring further research.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
Background:
- Randomized clinical trials confirm statin efficacy in preventing coronary heart disease (CHD).
- Statins slow coronary atherosclerosis progression and reduce morbidity and mortality rates.
- Three trials specifically assessed long-term statin effects in post-myocardial infarction patients.
Purpose of the Study:
- To evaluate the benefits of statin therapy in coronary heart disease (CHD) prevention.
- To assess the impact of statins on mortality and major coronary events.
- To investigate the optimal low-density-lipoprotein (LDL) cholesterol target for treatment.
Main Methods:
- Review of randomized clinical trials on statin use in CHD prevention.
- Analysis of data from the Scandinavian Simvastatin Survival Study (4S), Cholesterol and Recurrent Events (CARE) trial, and Long Term Intervention with Pravastatin in Ischemic Disease (LIPID) study.
- Post hoc analysis of trial results to determine optimal LDL cholesterol goals.
Main Results:
- Statins significantly reduce coronary mortality and total mortality rates.
- Significant reductions in major coronary events and CHD mortality were observed across trials.
- Post hoc analyses show conflicting evidence regarding the optimal LDL cholesterol target, with some suggesting benefits below current recommendations and others finding no additional benefit below 125 mg/dL.
Conclusions:
- Statin therapy is highly effective in reducing cardiovascular events and mortality in patients with and without existing CHD.
- There is ongoing debate regarding the ideal LDL cholesterol level for maximizing benefits, necessitating further prospective studies.
- Aggressive LDL cholesterol lowering may offer additional benefits, but this requires confirmation in future research.
Abstract:
Several randomized clinical trials using statins in the prevention of coronary heart disease (CHD) have demonstrated benefit, both in terms of retardation of the progression of signs of coronary atherosclerosis and in reduced morbidity and mortality rates. Three of these trials have examined the long-term effect of statins in patients with previous myocardial infarction. The Scandinavian Simvastatin Survival Study (4S) showed that a mean reduction of low-density-lipoprotein (LDL) cholesterol by 35% reduced coronary mortality rates by 42% and total mortality rates by 30%. In the Cholesterol and Recurrent Events trial, a 28% reduction in LDL-cholesterol was associated with a reduction in major coronary events of 24%. In the Long Term Intervention with Pravastatin in Ischemic Disease study, the 25% LDL-cholesterol reduction produced a 24% reduction in coronary disease mortality rates and 22% reduction in death from all causes. All event reductions were highly statistically significant. Other trials using statins in patients without signs of CHD have yielded similar risk reductions. Post hoc analysis of the results of the trials have produced diverging indications as to what is the optimal goal of cholesterol lowering. Analysis of the 4S indicates that aggressive treatment aiming at LDL-cholesterol levels lower than the current recommendations of expert panels in the United States and in Europe may yield additional benefit. This strategy finds some support in epidemiological studies and in a study with angiographic end points. Analysis of two trials using pravastatin contradict this and conclude that there is little or no additional benefit of reducing LDL-cholesterol below 125 mg/dL (3.2 mmol/L). Future studies need to address this question prospectively.